JANUARY/FEBRUARY

Vol 10, No 1 CME Pretest

This Journal provides 4 hours of Category 1 Continuing Medical Education

Complimentary CME Credits

Physicians can earn 4 credit hours of Category 1 for the Physician's Recognition Award of the American Medical Association by reading the material in this issue and successfully answering the questions in the posttest at the end of this issue. Complete instructions are given on the posttest pages. Successfully answering 30 or more questions will earn 4 credit hours.

Educational Objectives

After reading this issue of Cancer Control, clinicians will be expected to:

• discuss the mechanisms of hematopoietic stem cells and hematopoiesis,

• be aware of the role of stem-cell transplantation in hematologic malignancies,

• understand the effects of high-dose chemotherapy for patients with breast cancer and germ cell tumors,

• recognize and treat catheter-related bloodstream infections, and

• understand the impact of enrollment in cancer clinical trials on costs.

This program was planned in accordance with ACCME Essentials.

Release Date: January 1, 2003
Expiration Date: January 1, 2004

1. What term is used to describe the potential for progenitor and even relatively mature cells to be “reprogrammed” to recover some of their stem cell properties?

a. plasticity
b. retrogenesis
c. embryonization
d. differentiation

2. What is the average treatment-related mortality reported from nonmyeloablative allo-SCT for hematologic malignancies?

a. 15%
b. 32%
c. 56%
d. 67%

3. The adjuvant PEGASE 01 trial compared FEC100 alone vs FEC100 plus 1 cycle of high-dose cyclophosphamide, mitoxantrone, and melphalan followed by peripheral blood stem-cell infusion in patients under 60 years of age with more than 7 nodes involved by breast cancer metastasis. Which study arm had the best overall survival?

a. no difference between arms
b. high-dose chemotherapy
c. standard chemotherapy